Effects of 12ￂ weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin

Summary Aims Two multiple-dose phase II studies were conducted in subjects with primary hypercholesterolemia to evaluate the LDL-C lowering efficacy, safety, and tolerability of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Methods The results from the two phase II,...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cardiovascular therapeutics 2018-02, Vol.36 (1)
Hauptverfasser:	Fazio, Sergio, Robertson, David G, Joh, Tenshang, Wan, Hong, Riel, Tom, gues, Philippe, Baum, Charles M, Garzone, Pamela D, Gumbiner, Barry
Format:	Artikel
Sprache:	eng
Schlagworte:	Low density lipoprotein Monoclonal antibodies Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!